New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2012
10:20 EDTTNB, SIGA, MAKO, SNCR, RHHBY, EA, SYNC, NCMI, BP, ERJ, ACM, EPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AECOM Technology (ACM) downgraded to Underperform from Buy at BofA/Merrill... BP (BP) downgraded to Underweight from Equal Weight at Barclays... El Paso (EP) downgraded to Underweight from Neutral at Atlantic Equities... Embraer (ERJ) downgraded to Neutral from Buy at Citigroup... Mako Surgical (MAKO) downgraded to Neutral from Buy at Mizuho... National CineMedia (NCMI) downgraded to In-Line from Outperform at Imperial Capital... Roche (RHHBY) downgraded to Neutral from Overweight at JPMorgan... SIGA Technologies (SIGA) downgraded to Sector Perform from Outperform at RBC Capital... Synacor (SYNC) downgraded to Underperform from Buy at BofA/Merrill... Synchronoss (SNCR) downgraded to Market Perform from Outperform at Wells Fargo... Thomas & Betts (TNB) downgraded to Neutral from Outperform at RW Baird... Electronic Arts (EA) downgraded to Market Perform from Outperform at William Blair.
News For ACM;BP;EP;ERJ;MAKO;NCMI;RHHBY;SIGA;SYNC;SNCR;TNB;EA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 16, 2015
16:14 EDTSIGASIGA Technologies appeals judgment of Delaware Court of Chancery
SIGA Technologies (SIGA) announced that it has filed a notice of appeal from the judgment of the Delaware Court of Chancery awarding PharmAthene (PIP) expectation damages. On January 15, the Court of Chancery entered a judgment awarding PharmAthene a lump sum of $113,116,985 plus prejudgment interest, costs and fees. The total amount of the judgment is $194,649,041.74. William J. Haynes II, SIGA's General Counsel, commented, “We believe the decision to award expectation damages is not supported by law with the amount of the award being completely speculative, conjectural and arbitrary. We are confident in the strength of our grounds for appeal, and will ask the Supreme Court of Delaware to overturn this judgment.” Dr. Eric A. Rose, SIGA’s CEO, also commented, “We remain absolutely committed to performing under SIGA's contract with BARDA, obtaining FDA approval for our smallpox drug, Tecovirimat, and growing our company, and we have ample resources to do so.” While SIGA believes it has strong grounds on which to base its appeal, no assurance can be given that its appeal will be successful.
10:24 EDTBPOptions point to oil falling to near $30 per barrel, Merrill Lynch says
Subscribe for More Information
10:01 EDTBPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:29 EDTBPBP downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded BP to Underweight saying it expects 2015/2016 consensus estimates for Big Oil names to decline by more than 50% as oil price outlooks come down.
07:37 EDTBPBP downgraded to Hold from Buy at Canaccord
06:49 EDTBPOil prices climb after IEA says production falling, Reuters reports
Oil prices rebounded today after the International Energy Agency, or IEA, said it saw signs that oil production was falling in some areas, including North America, according to Reuters. "A price recovery...may not be imminent, but signs are mounting that the tide will turn," Reuters quoted the IEA as saying. Oil prices could rebound in the second half of the year, the IEA indicated, the news service reported. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
06:21 EDTRHHBYRoche acquires Trophos for EUR120M plus contingent payments
Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos’s proprietary screening platform generated olesoxime, TRO19622, which is being developed for SMA – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a pivotal phase II clinical trial with olesoxime in SMA showed a beneficial effect on the maintenance of neuromuscular function in individuals with Type II and non-ambulatory Type III SMA, as well as a reduction in medical complications associated with the disease. These data were first presented in April 2014 at the annual meeting of the American Academy of Neurology. Under the terms of the agreement, Trophos’s shareholders will receive an upfront cash payment of EUR 120M, plus additional contingent payments of up to EUR 350M based on achievement of certain predetermined milestones.
06:01 EDTSIGASiga ordered to pay $194M to PharmAthene in smallpox drug case, Bloomberg says
Siga Technologies (SIGA) was ordered to pay more than $194M to PharmAthene (PIP) in a dispute over the medicine that caused Siga to seek bankruptcy protection in 2014, reports Bloomberg. Delaware Chancery court Judge Donald Parsons said Siga executives breached their obligation to negotiate a licensing agreement for the smallpox medicine in good faith. Reference Link
05:45 EDTEADecember NPD video game software sales dropped 2%, says Piper Jaffray
Piper Jaffray notes December NPD video game software sales fell 2% year-over-year, with the full quarter down 6% and 2014 down 13%. Piper attributes the declines to legacy weakness and a portion of sales shifting to full-game downloads. The firm expects software growth in 2015 and maintains Overweight ratings on Activision Blizzard (ATVI), Electronic Arts (EA), GameStop (GME) and Take-Two (TTWO).
January 15, 2015
17:53 EDTBPBP may pay up to $13.7B in fines for Deepwater Horizon Gulf spill case, WSJ says
BP may have to pay a maximum $13.7B in fines for the oil that escaped into the Gulf of Mexico in the 2010 Deepwater Horizon incident, says the Wall Street Journal. A federal judge ruled that the company is liable for just over 3M barrels of oil spilled in the disaster, added the Wall Street Journal. Reference Link
16:11 EDTSIGAPharmAthene says court enters final order in $194.65M SIGA litigation
PharmAthene (PIP) announced that the Delaware Court of Chancery has entered its Final Order and Judgment in the company's litigation against SIGA Technologies (SIGA). The court's judgment against SIGA totaled $194.65M, including $113.12M in lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat, and $81.53M in pre-judgment interest and attorneys' and expert witness fees. The court's determination, along with the decision itself, will remain subject to appeal by SIGA to the Delaware Supreme Court. Because SIGA has filed for protection under the Federal bankruptcy laws, PharmAthene said it is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. PharmAthene's ability to collect a money judgment from SIGA remains subject to further proceedings in the bankruptcy court, it added.
16:01 EDTSIGASIGA to pay $194.1M in dispute over smallpox drug, Bloomberg says
Subscribe for More Information
10:00 EDTERJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:20 EDTERJEmbraer upgraded to Neutral from Underperform at Credit Suisse
Subscribe for More Information
06:10 EDTBPBP cutting 300 jobs in onshore roles, Daily Mail reports
Subscribe for More Information
January 14, 2015
14:07 EDTSYNCSynacor acquires NimbleTV, terms not disclosed
Subscribe for More Information
10:30 EDTRHHBYHuman Longevity signs genome sequencing pact with Roche unit
Human Longevity announced a multi-year agreement with Genentech, a member of the Roche Group, to conduct whole genome sequencing of tens of thousands of de-identified samples from Genentech. HLI, using proprietary tools and unique expertise, will sequence genomes to 30x coverage and analyze the data. Financial details of the agreement were not disclosed.
07:14 EDTSYNCSynacor, Verizon FiOS expand partnership
Subscribe for More Information
06:54 EDTBPEnergy Department says oil production to rise this year, NY Times says
Subscribe for More Information
05:33 EDTERJEmbraer sees negative free cash flow of approximately $400M in 2014
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use